First-in-human, open-label, phase 1/2 study of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced cancers

  1. Felip, E.
  2. Moreno, V.
  3. Morgensztern, D.
  4. Curigliano, G.
  5. Rutkowski, P.
  6. Trigo, J.M.
  7. Calvo, A.
  8. Kowalski, D.
  9. Cortinovis, D.
  10. Plummer, R.
  11. Maio, M.
  12. Ascierto, P.A.
  13. Vladimirov, V.I.
  14. Cervantes, A.
  15. Zudaire, E.
  16. Hazra, A.
  17. T’jollyn, H.
  18. Bandyopadhyay, N.
  19. Greger, J.G.
  20. Attiyeh, E.
  21. Xie, H.
  22. Calvo, E.
Revista:
Cancer Chemotherapy and Pharmacology

ISSN: 1432-0843,  0344-5704

Any de publicació: 2022

Volum: 89

Número: 4

Pàgines: 499-514

Tipus: Article

DOI: 10.1007/S00280-022-04414-6 GOOGLE SCHOLAR lock_openAccés obert editor
Font de les dades: Scopus